CUHFT: For use by Consultant Neurologists and Geriatricians ONLY.
Non-formulary at all other Trusts and in Primary Care
Regular LFT monitoring required
Previously withdrawn due to liver problems. Relaunched August 2005.
NWAFT only (HOSPITAL ONLY): For use when patients cannot be stabilised on entacapone and does not meet the criteria below in relation to persistent diarrhoea.
Specialist Initiation (CUHFT and NWAFT) 2-month trial by secondary care for continuation in primary care only - For patientswith Parkinson’s and motor fluctuations who are eligible for a 2 month trial of opicapone will necessarily first have had a trial of entacapone, and will have experienced the unacceptable adverse effect of persistent diarrhoea causing incontinence, or frequent passing of loose stool disturbing sleep or lifestyle, as defined by Bristol stool chart 6/7, which resolves when stopping entacapone.
Non-formulary at all other Trusts.
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Available Over the Counter. Consider Self Care
Formulary - Can be prescribed in both secondary and primary care.
Formulary - Specialist Advice, secondary care advice provided for primary care initiation.
Formulary - Specialist initiation without shared care guidance.
Formulary - Specialist initiation with shared care guidance.
Restricted - Hospital only, not to be prescribed in primary care.
Not recommended for prescribing. Switch to alternative cost-effective option.
Not recommended for prescribing in primary or secondary care.
Not recommended as no formal application made for addition to the formulary. Contact relevant pharmacy team for further information.